CH SUPPLY CHAIN (03708) plans to issue approximately 20% discount to subscribe for 1.1188 billion shares, raising net proceeds of HK $13.42 million.
The Chinese supply chain industry (03708) has released an announcement that on January 6, 2025, subscriber I (Qingda Zongheng Holdings...
CH SUPPLY CHAIN (03708) announced that on January 6, 2025, Subscriber I (Qingdaozongheng Holdings Group Limited (Qingdaozongheng)) and Subscriber II (Mr. Li Guoxun, a Hong Kong merchant) entered into a subscription agreement with the company. According to the general authorization, Subscriber I and Subscriber II have conditionally agreed to subscribe and the company has conditionally agreed to issue 670.6 million subscription shares and 448.2 million subscription shares to Subscriber I and Subscriber II respectively, at a subscription price of HK$0.012 per share, with a total consideration of HK$13.4256 million.
The subscription shares represent approximately 20% of the company's issued share capital as of the date of this announcement; and approximately 16.67% of the enlarged issued share capital of the company after the issuance of 1.1188 billion subscription shares. The subscription price of HK$0.012 per share represents a discount of approximately 20% compared to the closing price of HK$0.015 per share reported on the Stock Exchange on January 6, 2025.
The total proceeds raised from the subscription will be approximately HK$13.4256 million. After considering the estimated expenses related to the subscription, the net proceeds from the subscription are estimated to be approximately HK$13.42 million, or a net price of HK$0.012 per share. The group intends to use the approximately HK$13.42 million for general working capital and/or to invest in potential new projects identified by the group in the future.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025